Grifols Receives Takeover Interest From Its Founding Family, Brookfield Fund; to Go Private

Seeking AlphaJul 8 06:11 ET

Grifols completed the sale of 20% of Shanghai RAAS Blood Products shares and reached a global strategy cooperation agreement with Haier Group.

With today's completed trade announcement, Grifols and Haier will collaborate through Shanghai RAAS to enhance China's medical care system. Through a stock purchase agreement, Grifols is selling 20% of Shanghai RAAS's shares to Haier Group for RMB 12.5 billion (approximately 1.6 billion euros). Grifols and Shanghai RAAS have extended their exclusive agent agreement for albumin for the next 10 years, and Shanghai RAAS can choose to extend it until 2044. All of Grifols' earnings will be used to fulfill its deleveraging commitments. Shanghai, June 18, 2024 / PR Newswire / - Global medical and health enterprises.

PR NewswireJun 18 08:02 ET

6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 14 13:20 ET · Announcements

Grifols 2023 Annual Report on Form 20-F Filed With the SEC

Yahoo FinanceApr 19 16:42 ET